MRI Assisted Focal Boost Integrated With HDR Monotherapy Study in Low and Intermediate Risk Prostate Cancer Patients (MARS)
Radiation therapy plays an important role in the management of prostate cancer. In recent
years it has become evident that higher doses of radiation are required to optimize disease
control. The limiting factor of escalating dose to the prostate is the surrounding normal
tissue. Despite advances in escalating radiation therapy, failures still occur in 20-30% of
patients most often at the site of the original primary disease. As such there is growing
interest in further dose escalating to the area of primary disease burden.The aim of this
work is to look at the feasibility and toxicities of an integrated focal boost to whole
gland prostate treatment using high dose rate brachytherapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society